INDIA MARKET LENS
Companies◆ Mixed

Lactogen Pro 1 Easy To 'Digest' For Babies? FSSAI Pulls Up Nestlé India For Scientific Proof

Nestle India is in focus.

· NDTV Profit

FSSAI has sought scientific evidence from Nestlé India for digestion and immunity claims on infant formula products, while Zydus Wellness faces scrutiny over Complan's growth, memory and immunity-related advertisements.

Against that, the stock is -1.8% on the day at ₹1,167.00, and has returned -23.3% over three months. It sits 24% below its 52-week high. The fmcg sector has moved -10.7% over the same period, so Nestle India is running 12.6 points behind its peers.

For Nestle India, the question is how much of this is already reflected in the price and how much re-rates the fmcg peer set alongside it.

  • In focus: Nestle India (Nestlé India) (NESTLEIND), in FMCG.
  • On the day, 0 of 2 are higher: Nestle India (Nestlé India) leads at -1.8% and Zydus Wellness trails at -3.5%.
  • Over three months: Nestle India (Nestlé India) -23.3% against FMCG -10.7% (12.6 points behind); Zydus Wellness -18.2% against FMCG -10.7% (7.5 points behind).
Figures for the companies in this story
CompanyPriceDay1M3MFrom 52-wk highVolume vs 20-dayMarket cap
Nestle India (Nestlé India)NESTLEIND · FMCG₹1,167.00-1.8%-10.9%-23.3%-24.2%0.8×—
Zydus WellnessZYDUSWELL · FMCG₹462.75-3.5%-9.8%-18.2%-23.2%1.0×—

FMCG

1M -4.9% · 3M -10.7%

Nestle India (Nestlé India), Zydus Wellness

Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.